SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy’s Laboratories launches Ropinirole Hydrochloride XR tablets

07 Jun 2012 Evaluate

Dr Reddy’s Laboratories has launched Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg), a bioequivalent generic version of REQUIP XL tablets in the US market, following United States Food & Drug Administration (USFDA’s) approval for Dr Reddy’s ANDA for Ropinirole Hydrochloride XR (Extended Release).

The REQUIP XL brand has US sales of approximately $58 million for the most recent twelve months ending March 2012 according to the IMS Health.

Dr Reddy’s Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg) are available in 30 and 90 count bottles sizes, 8 mg and 12 mg are available  in 30 count bottle sizes.

Dr. Reddys Labs. Share Price

1366.50 -9.80 (-0.71%)
30-Jun-2026 13:51 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1868.95
Dr. Reddys Labs. 1366.50
Cipla 1471.70
Zydus Lifesciences 1119.85
Lupin 2427.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: